(September 26, 2020)
Scientific Organization:
Prof. Dr. Jesús K. Yamamoto-Furusho, Mexico City
Program
Welcome
J.K. Yamamoto-Furusho,
Chair: F. Gomollón, Zaragoza; J.K. Yamamoto-Furusho, Mexico City
Epidemiological and clinical aspects of SARS-CoV-2 infection in IBD patients
J.K. Yamamoto-Furusho, Mexico City
Discussion
What is the role of 5-aminosalicylates (5-ASA) in the management of patients with IBD in the pandemic era?
F. Gomollón, Zaragoza
Discussion
The impact of the use of local and systemic steroids in the clinical course of IBD patients in the Covid-19 era
R. Panaccione, Calgary
Discussion
What is the clinical impact in the use of immunomodulators in patients with IBD and SARS-CoV-2 infection and Covid-19?
S. Ghosh, Birmingham
Discussion
Therapy with vedolizumab in the times of Covid-19
S. Schreiber, Kiel
Discussion
Is ustekinumab safe in the treatment of IBD patients with SARS-CoV-2 infection or Covid-19?
R. Ungaro, New York
Discussion
What is the recommendation about the use of tofacitinib in UC patients with SARS-CoV-2 infection or Covid-19?
W.J. Sandborn, San Diego
Discussion
Closing remarks
J.K. Yamamoto-Furusho, Mexico City